Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis

Diabetes, Obesity and Metabolism

Volumn 18, Issue 8, 2016, Pages 783-794

  Zaccardi, F ^a,b   Webb, D R ^a,b   Htike, Z Z ^a,b   Youssef, D ^a,b   Khunti, K ^a,b   Davies, M J ^a,b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

canagliflozin; dapagliflozin; empagliflozin; meta analysis; review; SGLT2 inhibitor; systematic

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; B CELL ACTIVATING FACTOR; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL EFFECTIVENESS; DIET RESTRICTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BODY WEIGHT; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HYPOGLYCEMIA; METABOLISM; NETWORK META-ANALYSIS; ODDS RATIO; TREATMENT OUTCOME; URINARY TRACT INFECTION;

B-CELL ACTIVATING FACTOR; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BODY WEIGHT; CANAGLIFLOZIN; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FASTING; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; NETWORK META-ANALYSIS; ODDS RATIO; REPRODUCTIVE TRACT INFECTIONS; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; WEIGHT LOSS;

EID: 84969915634     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12670     Document Type: Article

References (74)

1. Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773–795.
2. Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 2014; 383: 2008–2017.
3. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015; 58: 429–442.
4. Abdul-Ghani MA, DeFronzo RA. Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport. J Intern Med 2014; 276: 352–363.
5. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 2012; 8: 495–502.
6. Sutton A, Ades AE, Cooper N, Abrams K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008; 26: 753–767.
7. Jansen JP, Trikalinos T, Cappelleri JC et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health 2014; 17: 157–173.
8. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006–1012.
9. Hoaglin DC, Hawkins N, Jansen JP et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011; 14: 429–437.
10. Hutton B, Salanti G, Caldwell DM et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015; 162: 777–784.
11. Higgins JP, Altman DG, Gøtzsche PC et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
12. Harris R, Bradburn M, Deeks J, Harbord R, Altman D, Sterne J. Metan: fixed- and random-effects meta-analysis. Stata J 2008; 8: 3–28.
13. Multiple-Treatments Meta-Analysis. Using STATA for network meta-analysis. Available from URL: http://www.mtm.uoi.gr/index.php/stata-routines-for-network-meta-analysis. Accessed 15 February 2016.
14. White IR. Multivariate random-effects meta-regression: updates to mvmeta. Stata J 2011; 11: 255–270.
15. White IR, Barrett JK, Jackson D, Higgins JP. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods 2012; 3: 111–125.
16. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE Decision Support Unit technical support document 2: a generalised linear model framework for pairwise and network meta-analysis of randomised clinical trials. 2014. Available from URL: http://www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf. Accessed 15 February 2016.
17. Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One 2013; 8: e76654.
18. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011; 64: 163–171.
19. Jackson D, Barrett JK, Rice S, White IR, Higgins JP. A design-by-treatment interaction model for network meta-analysis with random inconsistency effects. Stat Med 2014; 33: 3639–3654.
20. Araki E, Tanizawa Y, Tanaka Y et al. Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2015; 17: 665–674.
21. Bailey CJ, Iqbal N, T'Joen C, List JF. Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 2012; 14: 951–959.
22. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013; 11: 43.
23. Bailey CJ, Morales Villegas EC, Woo V et al. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabet Med 2015; 32: 531–541.
24. Bode B, Stenlöf K, Harris S et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes. Diabetes Obes Metab 2015; 17: 294–303.
25. Bolinder J, Ljunggren Ö, Johansson L et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014; 16: 159–169.
26. Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care 2015; 38: 1218–1227.
27. DeFronzo RA, Lewin A, Patel S et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015; 38: 384–393.
28. Del Prato S, Nauck M, Durán-Garcia S et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab 2015; 17: 581–590.
29. Ferrannini E, Berk A, Hantel S et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 2013; 36: 4015–4021.
30. Forst T, Guthrie R, Goldenberg R et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014; 16: 467–477.
31. Haering HU, Merker L, Christiansen AV et al. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Res Clin Pract 2015; 110: 82–90.
32. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012; 66: 446–456.
33. Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, phase III study. Expert Opin Pharmacother 2014; 15: 1501–1515.
34. Jabbour SA, Hardy E, Sugg J, Parikh S. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care 2014; 37: 740–750.
35. Ji L, Ma J, Li H et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther 2014; 36: 84–100.
36. Kadowaki T, Haneda M, Inagaki N et al. Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study. Adv Ther 2015; 32: 306–318.
37. Kaku K, Kiyosue A, Inoue S et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab 2014; 16: 1102–1110.
38. Kovacs CS, Seshiah V, Merker L et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clin Ther 2015; 37: 1773–1788.
39. Lavalle-González FJ, Januszewicz A, Davidson J et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56: 2582–2592.
40. Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc 2014; 62: 1252–1262.
41. Leiter LA, Yoon KH, Arias P et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 2015; 38: 355–364.
42. Lewin A, DeFronzo RA, Patel S et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care 2015; 38: 394–402.
43. Matthaei S, Bowering K, Rohwedder K, Sugg J, Parikh S, Johnsson E. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes. Diabetes Obes Metab 2015; 17: 1075–1084.
44. Merker L, Häring HU, Christiansen AV et al. Empagliflozin as add-on to metformin in people with type 2 diabetes. Diabet Med 2015; 32: 1555–1567.
45. Neal B, Perkovic V, de Zeeuw D et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care 2015; 38: 403–411.
46. Ridderstrale M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014; 2: 691–700.
47. Roden M, Weng J, Eilbracht J et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013; 1: 208–219.
48. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycaemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473–1478.
49. Rosenstock J, Jelaska A, Frappin G et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycaemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 2014; 37: 1815–1823.
50. Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ. Impact of empagliflozin added-on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015; 17: 936–948.
51. Rosenstock J, Hansen L, Zee P et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 2015; 38: 376–383.
52. Schernthaner G, Gross JL, Rosenstock J et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; 36: 2508–2515.
53. Stenlöf K, Cefalu WT, Kim KA et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: 372–382.
54. Strojek K, Yoon KH, Hruba V, Sugg J, Langkilde AM, Parikh S. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther 2014; 5: 267–283.
55. Wilding JP, Charpentier G, Hollander P et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013; 67: 1267–1282.
56. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 2014; 16: 124–136.
57. Mathieu C, Ranetti AE, Li D et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care 2015; 38: 2009–2017.
58. Goring S, Hawkins N, Wygant G et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab 2014; 16: 433–442.
59. Taieb V, Pacou M, Schroeder M, Schubert A, Nielsen AT. Network meta-analysis (NMA) to assess relative efficacy measured as percentage of patients treated to HbA1c target with canagliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and sulphonylurea (MET + SU). Value Health 2015; 18: A598.
60. Taieb V, Pacou M, Schroeder M, Nielsen AT, Neslusan C, Schubert A. Bayesian network meta-analysis (NMA) to assess the relative efficacy of canagliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with insulin. Value Health 2015; 18: A598.
61. Taieb V, Pacou M, Schroeder M, Nielsen AT, Schubert A, Neslusan C. A network meta-analysis (NMA) to assess the longer-term relative efficacy of canagliflozin in patients with type 2 diabetes inadequately controlled on metformin. Value Health 2015; 18: A598.
62. Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open 2016; 6: e009417.
63. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.
64. Neal B, Perkovic V, de Zeeuw D et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)–a randomized placebo-controlled trial. Am Heart J 2013; 166: 217–223.
65. ClinicalTrials.gov. Available from URL: https://clinicaltrials.gov/ct2/show/NCT01730534. Accessed 15 February 2016.
66. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007; 261: 32–43.
67. Grempler R, Thomas L, Eckhardt M et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012; 14: 83–90.
68. Zambrowicz B, Freiman J, Brown PM et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012; 92: 158–169.
69. Rosenstock J, Cefalu WT, Lapuerta P et al. Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes Care 2015; 38: 431–438.
70. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; 38: 1687–1693.
71. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 2015; 38: 1680–1686.
72. Food and Drug Administration. Available from URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM461790.pdf. Accessed 15 February 2016.
73. Watts NB, Bilezikian JP, Usiskin K et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016; 101: 157–166.
74. Wu JHY, Foote C, Blomster J et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016 [Epub before print]. DOI: 10.1016/S2213-8587(16)00052-8.